Diagnosis of COPD and clinical course in patients with unrecognized airflow limitation

International Journal of COPD

Volumn 8, Issue , 2013, Pages 199-208

  Murphy, Daniel E ^a,b   Panos, Ralph J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Airflow limitation; COPD; Diagnosis; Veterans Healthcare Administration

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID;

ADULT; AGED; AIRFLOW LIMITATION; AMBULATORY CARE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; EMERGENCY WARD; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE STAGE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MORTALITY; OUTPATIENT; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; SPIROMETRY; UNITED STATES;

AIRFLOW LIMITATION; COPD; DIAGNOSIS; VETERANS HEALTHCARE ADMINISTRATION;

ADULT; COMORBIDITY; DIAGNOSTIC ERRORS; EARLY MEDICAL INTERVENTION; FEMALE; HEALTH SERVICES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; UNITED STATES; VETERANS HEALTH;

EID: 84876544805     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S39555     Document Type: Article

References (46)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256-1276.
2. National Institutes of Health, National Heart, Lung and Blood Institute. Morbidity and Mortality: 2012 Chartbook on Cardiovascular, Lung and Blood diseases. US Department of Health and Human Services, Public Health Service, NIH, Bethesda MD. http://www.nhlbi.nih.gov/.resources/docs/2012_ChartBook.pdf. Accessed March 13, 2013.
3. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1984-1994. Arch Intern Med. 2000;160(11):1683-1689.
4. Hoyert D L, Kochanek K D, Murphy SL. Death; Final Data for 1997. National vital statistics reports; vol 47 no 19. Hyattsville, MD: National Center for Health Statistics; 1999. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr47/nvs47-19.pdf. Accessed February 14, 2013.
5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498-1504.
6. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
7. Kochanek KD, Xu J, Murphy LS, Miniño AM, Kung HC. Deaths: Preliminary Data for 2009. National vital statistics reports; vol 59 no 4. Hyattsville, MD: National Center for Health Statistics; 2011. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_04.pdf. Accessed February 14, 2013.
8. Lundbäck B, Nyström L, Rosenhall L, Stjernberg N. Obstructive lung disease in northern Sweden: respiratory symptoms assessed in postal survey. Eur Respir J. 1991;4(3):257-266.
9. McDonald M, Hertz R P. Utilization of Veterans Affairs Medical Care Services by United States Veterans. New York: Pfizer US Pharmaceuticals; 2003. Available from: http://www.hawaii.edu/hivandaids/Utilization%20of%20Veterans%20Affairs%20Medical%20Care%20Services%20by%20US%20Veterans.pdf. Accessed Nov 2010.
10. Murphy DE, Chaudhry Z, Almoosa KF, Panos RJ. High prevalence of chronic obstructive pulmonary disease among veterans in the urban midwest. Mil Med. 2011;176(5):552-560.
11. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J. 2002;20(4):799-805.
12. Takahashi T, Ichinose M, Inoue H, Shirato K, Hattori T, Takishima T. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology. 2003;8(4):504-508.
13. Damarla M, Celli BR, Mullerova HX, Pinto-Plata VM. Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care. 2006;51(10):1120-1124.
14. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: The Nippon COPD Epidemiology study. Respirology. 2004;9(4):458-465.
15. Ackermann-Liebrich U, Kuna-Dibbert B, Probst-Hensch NM, et al; SAPALDIA Team. Follow-up of the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA 2) 1991-2003: methods and characterization of participants. Soz Praventivmed. 2005;50(4): 245-263.
16. de Marco R, Accordini S, Antò JM, et al. Long-term outcomes in mild/ moderate chronic obstructive pulmonary disease in the European community respiratory health survey. Am J Respir Crit Care Med. 2009;180(10): 956-963.
17. Burgel PR, Nesme-Meyer P, Chanez P, et al; Initiatives Bronchopneumopathie Chronique Obstructive Scientific Committee. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009; 135(4):975-982.
18. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114-120.
19. Mannino DM, Diaz-Guzman E. Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. Chest. 2012;141(1):73-80.
20. Ekberg-Aronsson M, Pehrsson K, Nilsson JA, Nilsson PM, Löfdahl CG. Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res. 2005;6:98.
21. American Thoracic Society Standardization of spirometry. AJRRCM. 1995;152:1107-1136.
22. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric Reference Values from a Sample of the General U.S. Population. Am J of Respir and Crit Care Med. 1999;159:179-187.
23. Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]. Available from: http://www.goldcopd.org. Accessed February 14, 2013.
24. GraphPad Software Quick Calcs [webpage on the Internet]. La Jolla, CA: GraphPad Software, Inc. Available from: http://graphpad.com/ quickcalcs/.Accessed August 1, 2012.
25. Buist AS, Vollmer WM, Sullivan SD, et al. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD. 2005;2(2):277-283.
26. Menezes AM, Perez-Padilla R, Hallal PC, et al; PLATINO Team. Worldwide burden of COPD in high and low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. Int J Tuberc Lung Dis. 2008;12(7):709-712.
27. Schirnhofer L, Lamprecht B, Firlei N, et al. Using targeted spirometry to reduce non-diagnosed chronic obstructive pulmonary disease. Respiration. 2011;81(6):476-482.
28. Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin DP, Wise RA. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(12):1301-1306.
29. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet. 2009;374(9696):1171-1178.
30. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.
31. Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care the SPiRiva Usual CarE (SPRUCE) study. Respir Res. 2007;8:45.
32. Anthonisen NR. Smoking, lung function, and mortality. Thorax. 2000;55(9):729-730.
33. Pelkonen M, Tukiainen H, Tervahauta M, et al. Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men. Thorax. 2000;55(9):746-750.
34. Pricea D, Freemana D, Cleland J, Kaplan A, Cerasoli F. Earlier diagnosis and earlier treatment of COPD in primary care. Prim Care Respir J. 2011;20(1):15-22.
35. Mapel DW, Robinson SB, Dastani HB, Shah H, Phillips AL, Lydick E. The direct medical costs of undiagnosed chronic obstructive pulmonary disease. Value Health. 2008;11(4):628-636.
36. Akazawa M, Halpern R, Riedel AA, Stanford RH, Dalal A, Blanchette CM. Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respir Med. 2008;102(12): 1744-1752.
37. Jansson SA, Lindberg A, Ericsson A, et al. Cost differences for COPD with and without physician-diagnosis. COPD. 2005;2(4):427-434.
38. Raczek AE, Seifer FD, et al; COPD-PS Clinician Working Group. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD. 2008;5(2): 85-95.
39. Calverley PM, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D. Development of a population-based screening questionnaire for COPD. COPD. 2005;2(2):225-232.
40. Bailey WC, Sciurba FC, Hanania NA, et al. Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ). Prim Care Respir J. 2009;18(3):198-207.
41. García-Rio F, Soriano JB, Miravitlles M, et al. Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health related quality of life. Chest. 2011;139(5):1072-1080.
42. Lederer DJ, Enright PL, Kawut SM, et al. Cigarette smoking associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Athersclerosis (MESA)-Lung Study. Am J Respir Crit Care Med. 2009;180(5):407-414.
43. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(5): 369-374.
44. Casanova C, de Torres JP, Aguirre-Jaíme A, et al. The progression of Chronic Obstructive Pulmonary Disease is Heterogeneous: The experience of the BODE cohort. Am J Respir Crit Care Med. 2011;184(9):1015-1021.
45. Brito-Mutunayagam R, Appleton SL, Wilson DH, Ruffin RE, Adams RJ; North West Adelaide Cohort Health Study Team. Global initiative for Chronic Obstructive Lung Disease Stage 0 is associated with excess FEV(1) decline in a representative population sample. Chest. 2010;138(3):605-613.
46. Walters JA, Walters EH, Nelson M, et al. Factors associated with misdiagnosis of COPD in primary care. Prim Care Respir J. 2011;20(4):396-402.